ArticleFrontiers in neurology
Association of steroid regimens and withdrawal with relapse risk in myasthenia gravis: a real-world cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corticosteroids (steroids) are the first-line immunotherapy for myasthenia gravis (MG), but the optimal steroid dosing regimen and effects of discontinuation remain unclear. This study aimed to investigate the associations of steroid regimens and steroid withdrawal with relapse risk in patients on steroid monotherapy. Methods: This cohort study, based on a prospective registry, included MG patients who achieved minimal manifestations or better status for at least 6 months with steroid monotherapy. The primary outcome was relapse. Group-based trajectory modeling (GBTM) identified steroid regimens, and Cox proportional hazards models with propensity score matching (PSM) assessed the association of regimens and steroid withdrawal with relapse. Results: Among 209 patients followed for a median of 54.0 months, 113 (54.1%) experienced relapses. GBTM identified three regimens reflecting baseline disease severity: "High Start, Fast Taper" (Regimen 1), "Moderate Start, Gradual Taper" (Regimen 2), and "Low Start, Slow Taper" (Regimen 3). Compared to the high-risk Regimen 1, Regimen 2 (HR = 0.27, Conclusion: In this steroid-responsive population, patients requiring a maximum induction dose > 0.83 mg/kg to achieve MM or better status have a significantly higher risk of future relapse. Steroid withdrawal is associated with a higher relapse risk compared to low-dose maintenance and should be approached with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.